Caution: PD-1 rechallenge after progression on immunotherapy (RCC)
Restarting immunotherapy alongside a targeted pill after immunotherapy has already failed adds side effects and no benefit.
CONTACT-03 (atezolizumab + cabozantinib vs cabozantinib) and TiNivo-2 (nivolumab + tivozanib vs tivozanib) were both negative. After IO progression, single-agent TKI (cabozantinib, tivozanib, axitinib) or belzutifan is standard; IO rechallenge is reserved for trials.
Pages like this
not linked directly; found by shared links- TrialCOSMIC-313
Shares Cabozantinib, Nivolumab, Renal cell carcinoma.
- CompanyAVEO Oncology (LG Chem)
Shares Tivozanib, Renal cell carcinoma.
- IdeaImmunotherapy downstaging to transplant with a safe washout
Shares Atezolizumab, Nivolumab, Immune checkpoint inhibitors.
- TrialCheckMate 9ER
Shares Cabozantinib, Nivolumab, Renal cell carcinoma.
- PairingIMDC risk → first-line regimen choice (RCC)
Shares Cabozantinib, Nivolumab, Renal cell carcinoma, Immune checkpoint inhibitors.
- PairingPD-1 blockade + VEGF inhibition
Shares Anti-angiogenic therapy, Atezolizumab, Renal cell carcinoma, Immune checkpoint inhibitors.
- PersonNeeraj Agarwal
Shares CONTACT-03, Renal cell carcinoma.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares Atezolizumab, Nivolumab, Immune checkpoint inhibitors.